Publication de Nicole Delepine : Pelvic Ewing sarcoma. 20 years experience.

Nicole delépine, le site officiel English Version Version Française
Accueil Site officiel ACCUEIL
Accueil du site officiel de Nicole Delepine
publication cancérologue réputé nicole delepine ostéosarcome
sarcome ewing publications du docteur nicole delepine
Publié sur : Annals of Oncology - volume 11, suppl 4. page 130 n° 594 p - 2000
Voir la version PDF de cette publication : Document PDF | Publication sur le site du média : Document www
Pelvic Ewing sarcoma. 20 years experience.
G. Delépine, F. Delépine, T. Sokolov, S. Alkallaf, H. Cornille, Nicole Delepine

Pelvic Ewing's sarcoma - 20 years experience.

Despite the improved survival of patients with Ewing's sarcoma, pelvic location remains a bad prognostic factor. This retrospective analysis tries to point out the reasons of such a situation, and to evaluate the impact of modern comprehensive approach on prognosis.

Material and methods:
From 1977/2 to 1998/6, 53 patients have been treated by our group for Ewing's sarcoma of pelvic bones. 32 were males, 21 females aged 6 to 35 years (median 16.3). At first screening 15 patients had already metastases and 38 presented with localised disease. Treatment included chemotherapy for all patients according to the current protocol at the time of presentation: four drugs (vincristine - dactinomycin - cyclophosphamide, doxorubicin: V Ad CA, five drugs (VAd CA + ifosfamide) or six drugs association (IVAd CA + etoposide orcisplatinium).
Local treatment used radiotherapy alone for 24 patients, surgery alone in 18 and a combination in 11 All patients have been followed up every 3 months for 2 years, every 6 months for 2 other years and then yearly.

With a median follow up often years, the 5 year actuarial event free survival rate for all patients is 31%; 13% for primary metastatic patients and 40% for patients seen with localised disease (p<0.001) In primary localised tumor the major prognostic factors are the adequacy of surgical resection (p<0.01) and the high dose intensity of chemotherapy, particularly during the induction (p<0.05). Patients treated by radiotherapy had a 44% risk of local recurrence 17% life expectancy, and a 13 months median survival compared to an 80% life expectancy and 80 months median survival for patients after wide resection.

1. Primary metastatic patients require new approach.
2. Early wide resection of the primary and adequate dose intensity of a 6 drugs chemotherapy give best results in pelvic Ewing's despite large tumoral volume or even incomplete response to preoperative chemotherapy.

publications médicales

sarcome d'ewing
nicole delepine cancer tumeur ostéosarcome
Facebook Tweeter